Gary Nachman
Stock Analyst at Canaccord Genuity
(1.96)
# 3,181
Out of 4,556 analysts
479
Total ratings
46.4%
Success rate
0.2%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $95 | $54.01 | +75.89% | 33 | Jul 23, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $273 → $282 | $253.30 | +11.33% | 44 | Jul 22, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Buy | $290 | $250.41 | +15.81% | 49 | Jul 17, 2026 | |
| ANIP ANI Pharmaceuticals | Initiated Coverage: Hold | $86 → $91 | $77.61 | +17.25% | 5 | Jul 17, 2026 | |
| ETON Eton Pharmaceuticals | Initiated Coverage: Buy | $60 | $43.58 | +37.68% | 1 | Jul 17, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $13 | $6.31 | +106.02% | 8 | Jun 23, 2026 | |
| ADMA ADMA Biologics | Maintained: Buy | $18 | $8.38 | +114.80% | 8 | Jun 14, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Buy | $62 | $48.30 | +28.36% | 13 | Jun 2, 2026 | |
| AMGN Amgen | Maintained: Hold | $366 | $366.05 | -0.01% | 4 | May 1, 2026 | |
| PCRX Pacira BioSciences | Maintained: Hold | n/a | $25.59 | - | 48 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16.81 | $9.10 | +84.72% | 7 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $20 | $2.26 | +784.96% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.84 | - | 5 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $40 | $5.34 | +649.06% | 2 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $3.94 | n/a | 18 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $22 | $15.95 | n/a | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $298 | $266.99 | n/a | 23 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $84.30 | n/a | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $100 | $0.0001 | n/a | 8 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $4 | $9.60 | n/a | 22 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $4 | $17.75 | n/a | 19 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $11.70 | n/a | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $78 | $15.03 | n/a | 5 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $14 | $17.01 | n/a | 17 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11.21 → $14.01 | $6.44 | n/a | 42 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $40 → $32 | $5.73 | n/a | 11 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 | $30.15 | n/a | 7 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $37.80 | n/a | 11 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $35 | $0.0001 | n/a | 10 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $4.00 | n/a | 6 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 | $1.76 | n/a | 3 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 → $12 | $17.36 | n/a | 5 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 | $19.30 | n/a | 14 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $3 | $0.0001 | n/a | 5 | Sep 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 | $44.17 | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $88.68 | n/a | 3 | Apr 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9.5 → $14 | $3.88 | n/a | 2 | Mar 21, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.8 | $13.71 | n/a | 2 | Oct 9, 2013 |
Ionis Pharmaceuticals
Jul 23, 2026
Maintained: Buy
Price Target: $95
Current: $54.01
Upside: +75.89%
AbbVie
Jul 22, 2026
Reiterated: Buy
Price Target: $273 → $282
Current: $253.30
Upside: +11.33%
Jazz Pharmaceuticals
Jul 17, 2026
Initiated Coverage: Buy
Price Target: $290
Current: $250.41
Upside: +15.81%
ANI Pharmaceuticals
Jul 17, 2026
Initiated Coverage: Hold
Price Target: $86 → $91
Current: $77.61
Upside: +17.25%
Eton Pharmaceuticals
Jul 17, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $43.58
Upside: +37.68%
Achieve Life Sciences
Jun 23, 2026
Reiterated: Buy
Price Target: $13
Current: $6.31
Upside: +106.02%
ADMA Biologics
Jun 14, 2026
Maintained: Buy
Price Target: $18
Current: $8.38
Upside: +114.80%
Scholar Rock Holding
Jun 2, 2026
Reiterated: Buy
Price Target: $62
Current: $48.30
Upside: +28.36%
Amgen
May 1, 2026
Maintained: Hold
Price Target: $366
Current: $366.05
Upside: -0.01%
Pacira BioSciences
Oct 6, 2025
Maintained: Hold
Price Target: n/a
Current: $25.59
Upside: -
Oct 2, 2025
Maintained: Buy
Price Target: $16.81
Current: $9.10
Upside: +84.72%
Aug 13, 2025
Maintained: Buy
Price Target: $3 → $20
Current: $2.26
Upside: +784.96%
Aug 4, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.84
Upside: -
Jul 31, 2025
Maintained: Buy
Price Target: $37 → $40
Current: $5.34
Upside: +649.06%
Jun 17, 2025
Maintained: Buy
Price Target: $7
Current: $3.94
Upside: n/a
Feb 20, 2025
Maintained: Buy
Price Target: $19 → $22
Current: $15.95
Upside: n/a
Jan 15, 2025
Reiterated: Buy
Price Target: $298
Current: $266.99
Upside: n/a
Aug 19, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $84.30
Upside: n/a
Mar 16, 2023
Rated: Buy
Price Target: $200 → $100
Current: $0.0001
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $5 → $4
Current: $9.60
Upside: n/a
Mar 2, 2023
Rated: Hold
Price Target: $4
Current: $17.75
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $35 → $30
Current: $11.70
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $83 → $78
Current: $15.03
Upside: n/a
Feb 27, 2023
Rated: Hold
Price Target: $14
Current: $17.01
Upside: n/a
Feb 24, 2023
Maintained: Hold
Price Target: $11.21 → $14.01
Current: $6.44
Upside: n/a
Feb 22, 2023
Rated: Buy
Price Target: $40 → $32
Current: $5.73
Upside: n/a
Feb 8, 2023
Rated: Hold
Price Target: $10
Current: $30.15
Upside: n/a
Jan 9, 2023
Rated: Buy
Price Target: $3
Current: $37.80
Upside: n/a
Nov 10, 2022
Maintained: Buy
Price Target: $60 → $35
Current: $0.0001
Upside: n/a
Aug 11, 2022
Reiterated: Buy
Price Target: $27 → $25
Current: $4.00
Upside: n/a
Aug 2, 2021
Maintained: Buy
Price Target: $180
Current: $1.76
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $13 → $12
Current: $17.36
Upside: n/a
May 11, 2020
Maintained: Hold
Price Target: $21
Current: $19.30
Upside: n/a
Sep 5, 2019
Maintained: Buy
Price Target: $9 → $3
Current: $0.0001
Upside: n/a
Sep 14, 2017
Maintained: Buy
Price Target: $80
Current: $44.17
Upside: n/a
Apr 27, 2017
Reiterated: Buy
Price Target: $138
Current: $88.68
Upside: n/a
Mar 21, 2016
Initiated Coverage: Hold
Price Target: $9.5 → $14
Current: $3.88
Upside: n/a
Oct 9, 2013
Maintained: Hold
Price Target: $6.8
Current: $13.71
Upside: n/a